Within the tumor, markers of immunogenic cell death [calreticulin and high-mobility group box 1 protein (HMGB1)] were increased, and the serum proinflammatory cytokines IL-6, TNFα, and IFNγ also were upregulated, as compared to other treatment groups. This evidence concerns the gene IL6 and neoplasm.